Ladenburg raised the firm’s price target on Ardelyx to $14.50 from $13.50 and keeps a Buy rating on the shares. Following earnings, the firm increased its price target based on the rapid initial XPHOZAH uptake during its initial launch, which increases the firm’s confidence in 2024 projections for the product.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
- Ardelyx price target lowered to $13 from $14 at Citi
- Ardelyx call volume above normal and directionally bullish
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- Ardelyx initiated with an Outperform at Leerink